This trial is evaluating whether carboplatin will improve 4 primary outcomes and 13 secondary outcomes in patients with Non-Small Cell Lung Carcinoma (NSCLC). Measurement will happen over the course of Up to 12 months.
This trial requires 160 total participants across 4 different treatment groups
This trial involves 4 different treatments. Carboplatin is the primary treatment being studied. Participants will be divided into 4 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
Carboplatin was well tolerated in this group of people with advanced NSCLC. The majority of people in the study were able to tolerate the drug. Side effects were manageable and included mild diarrhoea, vomiting, rash, fatigue, sleep disturbances, and constipation. Based on these data, carboplatin appears to be a reasonable option for people with advanced NSCLC receiving first line chemotherapy.
Carboplatin therapy was combined with all other treatments In a recent study except radiation. Although there is no proof that carboplatin may be combined safely with radiotherapy, it is still recommended as part of standard chemotherapy regimens because of its effectiveness.
Regardless of the histologic type, it is possible to cure neoplasms by surgical excision alone if appropriate therapy is administered; therefore, curative surgery is recommended for all neoplasms, regardless of histologic type.
It was suggested that breast cancer arose as a result of genetic changes which caused the stem cells in the mammary glands to become more susceptible to environmental carcinogens. The alterations in the gene expression profile were probably due to the accumulation of mutations during tumorigenesis.
There is no single age at onset of neoplasms, but there is a trend of earlier onset with increasing malignancy. This pattern is consistent across all histologic types except adenocarcinoma.
The high mortality associated with stage III rectal cancer and strong association between stage II and mortality of colon cancers suggest that patients must be considered seriously when considering surgery. It may be advisable to consider chemotherapy if possible and to discuss the decision with the patient before surgery. If surgery is planned, it should be performed only for curative motives.
A number of signs and symptoms can help identify a specific neoplasm based on its histology. These include color, size, shape, symmetry, and irregularity of the tumor. Other signs and symptoms can also be helpful, such as rapid growth rate, location of the tumor, and presence of metastatic disease.
The most common side effects of carboplatin were nausea (25%), fatigue (20%), diarrhea (18%), vomiting (17%), and anemia (<10%). Other less common side effects included constipation (>5%), rash (>4%), headache (<4%), cough (<4%), and pneumonitis (<4%). Most common toxicities occurred on days 4–12 after the first infusion of carboplatin. The incidence and severity of these adverse effects increased with higher doses and shorter infusion times.
Neoplasms by histological type occur throughout the body and not just in humans. The most common tumors are carcinomas (both squamous and nonsquamous) and lymphomas. They are not found very often in children. There are some cases of nonmelanoma skin cancers being more common in African Americans than Caucasians. Neurogenic tumors tend to be less common than other types. There are no significant differences in frequency of occurrence of neuroendocrine tumors according to race. [power(https://www.withpower.com/clinical-trials/neoplasms-by-histological-type) maybe helpful as you search for appropriate clinical trials.
Carboplatin is used extensively in metastatic ovarian carcinoma. The combination with paclitaxel has been shown to be active in patients with recurrent disease. It seems likely that further study of the use of carboplatin alone or combined with other agents such as paclitaxel, topotecan, or gemcitabine may reveal a role for this drug in the treatment of ovarian carcinoma.
The chemotherapy drugs used in metastatic bladder cancer often include carboplatin (Gemzar), paclitaxel (Taxol), vinorelbine (Elvograf), bacillus Calmette-Guérin (BCG), and methotrexate, as well as some other agents. This article discusses these drugs' usual indications and side effects, as well as possible interactions between the drugs. In the case of BCC, the discussion focuses on the role of cisplatin and cyclophosphamide as well as newer agents such as gemcitabine, mitomycin C, and ifosfamide.